Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities
Net loss	$ (108,995)	$ (89,298)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,145	1,245
Stock-based compensation	13,298	13,103
Research and development license expense	3,000
Change in fair value of warrant liability	1,199	(16)
Non-cash change in fair value of term loan	832	(597)
Debt issuance costs expensed under the fair value option	147
Impairment of long-lived assets	0	4,838
Non-cash lease expense	1,359	1,217
Other	296	750
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,734)	207
Accounts payable	(153)	(2,920)
Accrued expenses and other liabilities	6,289	(1,421)
Deferred revenue	(9,773)	(8,333)
Net cash used in operating activities	(93,090)	(81,225)
Cash flows from investing activities
Purchase of property, plant and equipment	(738)	(374)
Other	134	11
Net cash used in investing activities	(604)	(363)
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs	215,646	76,780
Proceeds from issuance of common stock pursuant to at-the-market offering, net of sales commissions and other offering costs	48,435
Prepayment of 2023 Trinity term loan	(40,612)
Proceeds from 2025 Trinity term loan, net	49,853
Proceeds from issuance of common stock upon exercise of warrants	225
Debt issuance costs for term loan		(18)
Proceeds from common stock issuances under ESPP	159	89
Proceeds from stock option exercises	1,220
Other	(337)	(167)
Net cash provided by financing activities	274,589	76,684
Net increase (decrease) in cash, cash equivalents and restricted cash	180,895	(4,904)
Cash, cash equivalents and restricted cash at the beginning of the period	141,636	146,540
Cash, cash equivalents and restricted cash at the end of the period	322,531	141,636
Cash and cash equivalents	319,767	139,036
Restricted cash	2,764	2,600
Supplemental disclosure of cash flow information:
Cash paid for interest	5,399	5,282
Supplemental disclosure of noncash investing and financing activities:
Proceeds allocated to Success Fee liability	217
Right-of-use assets obtained in exchange for lease liabilities	2,374
Purchase of research and development license not yet paid	3,000
Non-cash impact of exercise of liability classified warrants	1,637
Property, plant and equipment in accounts payable and accrued expenses	$ 41	346
Offering costs not yet paid		$ 46